Intralesional collagenase clostridium histolyticum study provides real-world analysis
- PMID: 28078227
- PMCID: PMC5182220
- DOI: 10.21037/tau.2016.11.14
Intralesional collagenase clostridium histolyticum study provides real-world analysis
Conflict of interest statement
Hellstrom WJ served as the primary investigator for the IMPRESS trials and is currently on a speaker's bureau and advisory board for Endo Pharmaceuticals. Haney NM and DeLay KJ have no conflicts of interest to declare.
Comment on
-
Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.Urology. 2016 Aug;94:143-7. doi: 10.1016/j.urology.2016.04.049. Epub 2016 May 17. Urology. 2016. PMID: 27211926
References
-
- Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207. 10.1016/j.juro.2013.01.087 - DOI - PubMed
-
- Yafi FA, Hatzichristodoulou G, DeLay KJ, et al. Review of Management Options for Patients With Atypical Peyronie's Disease. Sex Med Rev 2016. [Epub ahead of print]. - PubMed
Publication types
LinkOut - more resources
Full Text Sources